[Form 4] Hims & Hers Health, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Soleil Boughton, Chief Legal Officer of Hims & Hers Health, Inc. (HIMS), reported a sale of Class A common stock. On 09/17/2025 the reporting person disposed of 2,637 shares at $50.50 per share, leaving beneficial ownership of 166,404 shares following the transaction.

The Form 4 notes the sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 08/28/2024. The form is signed by an attorney-in-fact, Kimberly Mather, dated 09/19/2025.

Positive

• Sale executed under a Rule 10b5-1 trading plan, indicating a pre-established, compliant framework for the transaction
• Timely public disclosure of the transaction on Form 4 with signature by attorney-in-fact

Negative

• Insider disposed of 2,637 Class A shares, reducing beneficial ownership to 166,404 shares
• Transaction may be perceived negatively by some investors due to insider selling (document contains no explanation beyond the 10b5-1 plan)

Insights

Corporate Governance Expert

TL;DR Insider sale executed under a pre-established Rule 10b5-1 plan, indicating structured compliance with insider-trading policies.

The Form 4 discloses a sale of 2,637 Class A shares at $50.50 on 09/17/2025 by Soleil Boughton, the company's Chief Legal Officer. The filing explicitly states the trades were made pursuant to a Rule 10b5-1 plan adopted 08/28/2024, which is a common compliance mechanism to mitigate timing concerns around insider sales. The filing is signed by an attorney-in-fact and shows remaining beneficial ownership of 166,404 shares. This is a routine insider disclosure without additional governance concerns in the document.

Securities Analyst

TL;DR Transaction is a small-volume insider sale under a 10b5-1 plan; no other material changes disclosed.

The record shows a single non-derivative sale of 2,637 shares at $50.50, reducing the reporting person's holdings to 166,404 shares. The filing contains no derivative transactions, no amendments, and notes the sale mechanism (10b5-1 plan adopted 08/28/2024). From a market-impact perspective, the disclosed quantity appears modest relative to the remaining holdings; the Form 4 provides transparent execution details but does not include any new operational or financial information about the issuer.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Boughton Soleil

(Last) (First) (Middle)

2269 CHESTNUT STREET, #523

(Street)

SAN FRANCISCO CA 94123

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Hims & Hers Health, Inc. [ HIMS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	09/17/2025		S(1)		2,637	D	$50.5	166,404	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on August 28, 2024 by the Reporting Person.

Remarks:

	/s/ Kimberly Mather, Attorney-in-Fact for Soleil Boughton	09/19/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Soleil Boughton report on the Form 4 for HIMS?

The reporting person sold 2,637 Class A shares at $50.50 on 09/17/2025, leaving beneficial ownership of 166,404 shares.

Was the sale executed under a trading plan?

Yes. The Form 4 states the sales were effected pursuant to a Rule 10b5-1 trading plan adopted on 08/28/2024.

Who signed the Form 4 filing for the reporting person?

The form was signed by Kimberly Mather, Attorney-in-Fact, and dated 09/19/2025.

Did the Form 4 report any derivative transactions?

No. Table II for derivative securities contains no reported transactions in this filing.

How much did the reporting person receive per share in the transaction?

The reported price was $50.50 per share.